瑞士洛桑联邦理工学院科学家在药物开发方面取得了一个重要的里程碑，他们成功开发出靶向凝血酶的口服环肽药物。这种药物可以用于治疗各种疾病，如癌症、心脏病和糖尿病等。几十年来，大量蛋白质一直被认为是治疗疾病的关键，但这些蛋白质口服给药一直是一个难以克服的挑战。
该药物的给药途径非常方便，患者可以通过口腔摄入药物。与传统的注射给药方式相比，这种方式更为安全和便捷。此外，该药物的副作用较小，可以提高患者的治疗效果和生活质量。
目前，这种口服环肽药物已经进入临床试验阶段，预计未来有望成为医学上的一种重要治疗药物。
新闻翻译：
Title: Oral peptide drug for targeted thrombin shows promising results
Keywords: oral peptide drug, targeted thrombin, promising results
News content:
Scientists at the Eidgenössische Technische Hochschule in Lausanne in Switzerland have made a significant breakthrough in drug development with the development of an oral peptide drug for targeted thrombin. This drug can be used to treat various diseases, such as cancer, heart disease and diabetes. For decades, large proteins have been considered the key to treating diseases, but口服 administration of these proteins has always been a challenging task.
The oral peptide drug is administered through the mouth, which is a safer and more convenient method compared to traditional injection administration. In addition, the drug has minimal side effects, allowing for improved treatment outcomes and quality of life for patients.
At present, the oral peptide drug is in the clinical trial phase, and it is expected that it will become an important medical treatment drug in the future.
【来源】http://www.chinanews.com/life/2023/12-30/10137965.shtml
Views: 1